Estrogen Blockers Market Report 2024

This Estrogen Blockers market report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.

The estrogen blockers market size has grown strongly in recent years. It will grow from $8.72 billion in 2023 to $9.35 billion in 2024 at a compound annual growth rate (CAGR) of 7.1%. The growth observed during the historic period can be attributed to a rise in prostate cancer prevalence, an increase in hormone-related disorders, and greater adoption of hormone replacement therapy (HRT).

The estrogen blockers market size is expected to see strong growth in the next few years. It will grow to $12.37 billion in 2028 at a compound annual growth rate (CAGR) of 7.3%. The anticipated growth during the forecast period can be attributed to the increasing prevalence of breast cancer, growing awareness and screening initiatives, a rise in estrogen-related conditions worldwide, and the expanding use of estrogen blockers beyond cancer treatment. Key trends expected to drive this growth include advancements in the development of estrogen blockers, the discovery of novel blockers with enhanced efficacy, strategic partnerships among market players, and new product approvals.

The increasing incidence of breast cancer is projected to drive the growth of the estrogen blocker market. Breast cancer originates in the breast tissue, primarily affecting the milk ducts and lobules, and arises from mutations in normal breast cells that lead to uncontrolled growth and tumor formation. The rise in breast cancer cases can be attributed to factors such as an aging population, lifestyle changes such as higher alcohol consumption and sedentary behavior, and improved detection through advanced screening and diagnostic methods. Estrogen blockers are used in breast cancer treatment by inhibiting the hormone estrogen, which can fuel the growth of certain breast cancer cells. These blockers are effective in slowing or halting the growth of hormone receptor-positive breast cancers, aiding in treatment and potentially reducing the risk of recurrence. For instance, in January 2024, the Australian Institute of Health and Welfare reported that 20,458 cases of breast cancer were diagnosed in females in 2023, reflecting an age-standardized incidence rate of 128.6 cases per 100,000 females. This is a slight increase from the 20,004 cases diagnosed in 2022, with an age-standardized incidence rate of 128.2 cases per 100,000 females. This rising prevalence is expected to fuel growth in the estrogen blocker market.

Companies in the estrogen blocker market are concentrating on developing advanced drugs that combine AKT (Protein Kinase B) inhibitors with selective estrogen receptor degraders (SERDs) to improve treatment efficacy and address resistance in breast cancer therapy. This combination therapy targets survival pathways in cancer cells and degrades estrogen receptors, aiming to inhibit tumor growth and overcome resistance to hormonal treatments. For example, in November 2023, AstraZeneca, a UK-based pharmaceutical company, received FDA approval for Truqap (capivasertib), an AKT inhibitor, used in conjunction with Faslodex (fulvestrant), a SERD. This approval is for treating adult patients with hormone receptor (HR)-positive, HER2-negative locally advanced or metastatic breast cancer with specific biomarker alterations, such as PIK3CA, AKT1, or PTEN. This is particularly notable for patients who have progressed on at least one endocrine-based therapy or experienced recurrence within 12 months after completing adjuvant therapy.

In July 2024, Exscientia, a UK-based biotechnology company, acquired GT Apeiron's stake in its oral CDK7 inhibitor program for an undisclosed amount. This acquisition enhances Exscientia's oncology portfolio and positions the company to expand into combination therapies for HR+/HER2- breast cancer by late 2024. This development aligns with Exscientia's commitment to AI-driven drug design aimed at developing highly effective cancer treatments. GT Apeiron is a US-based expert in applied artificial intelligence and drug discovery, providing valuable expertise to support Exscientia's initiatives.

Major companies operating in the estrogen blockers market are Pfizer Inc, F. Hoffmann-La Roche AG, Merck & Co. Inc, Novartis AG, Sanofi S.A, AstraZeneca PLC, GlaxoSmithKline plc, Eli Lilly and Company, Viatris Inc, Teva Pharmaceutical Industries Ltd., Fresenius Kabi AG, Sun Pharmaceutical Industries Ltd., Ipsen S.A., Cadila Pharmaceuticals Ltd., Intas Pharmaceuticals Limited, Dr. Reddy's Laboratories Ltd., Hikma Pharmaceuticals PLC, Amneal Pharmaceuticals Inc., Lupin Limited, Glenmark Pharmaceuticals Limited, Alvogen Inc., Alembic Pharmaceuticals Limited, Olema Pharmaceuticals Inc, Cipla Inc, Criterium Inc.

North America was the largest region in the estrogen blockers market in 2023. The regions covered in the estrogen blockers market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the estrogen blockers market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Estrogen blockers are substances that inhibit the effects of estrogen in the body by either binding to estrogen receptors or reducing estrogen production. They are primarily used to treat estrogen receptor-positive breast cancer by preventing estrogen from promoting cancer cell growth. Additionally, estrogen blockers help manage conditions such as gynecomastia in men, endometriosis, and certain types of infertility by adjusting hormone levels.

The main types of estrogen blockers include selective estrogen receptor modulators (SERMs), aromatase inhibitors, estrogen receptor downregulators (ERDs), and other related substances. SERMs are a class of drugs that interact with estrogen receptors, acting as estrogen agonists in some tissues and antagonists in others. These products are distributed through hospital pharmacies, retail pharmacies, and online pharmacies, and are used for various applications such as treating breast cancer, hormone replacement therapy (HRT), infertility treatment, post-menopausal osteoporosis, and other conditions.

The estrogen blockers market research report is one of a series of new reports that provides estrogen blockers market statistics, including estrogen blockers industry global market size, regional shares, competitors with an estrogen blockers market share, detailed estrogen blockers market segments, market trends and opportunities, and any further data you may need to thrive in the estrogen blockers industry. This estrogen blockers market research report delivers a complete perspective on everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The estrogen blockers market consists of sales of tamoxifen, raloxifene, toremifene, anastrozole, letrozole, exemestane, and fulvestrant. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.